WeMed Medical Shines At SIMEM 2025 With Its Groundbreaking Interventional Surgery Solution

From April 9 to 12, SIMEM 2025 is being held at the Oran International Convention Center. WeMed Medical, a leading Chinese high-end medical equipment company, is making its debut at the event, showcasing its pioneering "DSA + Endovascular Robotic System + AI Imaging Processing Platform"-an integrated solution for interventional surgery.

On March 21, prior to the exhibition, WeMed Medical achieved a significant milestone with the official approval of its independently developed Coronary Intervention Surgery Control System by China's National Medical Products Administration (NMPA). It is the only domestically produced system to have gained approval through the NMPA's fast-track review for Class III innovative medical devices. This approval not only marks a transformative leap for China's high-end medical equipment industry-from technological follower to leader-but also signifies the completion of WeMed Medical's innovative "Eye-Hand-Brain" triad, powered by DSA, an Endovascular Robotic System, and an AI Imaging Processing Platform. With this breakthrough, a new era in interventional surgery has officially begun.

As the largest professional medical exhibition in North Africa, SIMEM is hosted by the Algerian Ministry of Health and has been successfully held for 27 consecutive editions, attracting more than 300 medical enterprises worldwide.

A SIMEM representative stated, "SIMEM serves as a crucial hub for connecting the African healthcare market with international technologies. WeMed Medical's innovative achievements provide a new paradigm for the global development of interventional medicine."

Developed independently by WeMed Medical, the Endovascular Robotic System -- China's first and only Class III innovative medical device approved via the NMPA's Green Channel Special Approval Process --has officially received market authorization from China's National Medical Products Administration (NMPA).

This milestone not only marks a transformative leap in China's high-end medical equipment sector from technological catch-up to global leadership, but also signifies the official completion of WeMed Medical's groundbreaking "Eye-Hand-Brain" innovation triad:

Eyes: The self-developed DSA equipment is deeply integrated with AI algorithms to precisely capture every detail of vascular lesions, providing the robot with an "ultra-high-definition road map."

Hands: With the intelligent bionic expertise of an Endovascular Robotic System, it acts as a "vehicle" navigating through blood vessels. Under the doctor's remote control, it flexibly and precisely performs various complex surgical procedures, supporting the full interventional process of catheters, guidewires, balloons, and stents.

Brain: Through deep learning and big data analysis, the AI imaging platform not only supports a wide range of advanced image post-processing functions but also provides doctors with accurate diagnostic insights and treatment plans, effortlessly enabling "autonomous navigation" within blood vessels.

The "Eye-Hand-Brain" integrated interventional surgery solution unifies imaging, surgical assistance, AI-driven decision-making, and automatic surgical navigation into a seamless system. This innovation enables the smooth integration of diagnosis, treatment, and navigation, effectively reducing doctors' exposure to occupational radiation. By transforming interventional procedures, it significantly improves surgical safety and efficiency, ultimately enhancing patient outcomes.

Additionally, the system supports dual-guidewire control, offers broad compatibility with various medical consumables, and covers the entire interventional process. It serves as an indispensable assistant for physicians, making interventional surgery more precise and efficient than ever before.

Following a dual-pronged international expansion strategy-combining both "bringing in" and "going out"-WeMed Medical is systematically broadening its global footprint. The company is prioritizing key markets across Southeast Asia, Central Asia, Africa, Latin America, and Europe.

A landmark achievement in this strategy was the successful acquisition of Italy-based Eurocolumbus, a move that established the Beijing-Milan Dual Center-a hub for international product R&D, manufacturing, sales, and marketing. This acquisition has reinforced WeMed Medical's international strategic presence, garnering widespread recognition from global customers for its technological innovation, superior product quality, and outstanding performance.

At SIMEM 2025, WeMed Medical not only demonstrated China's leadership in high-end medical equipment innovation but also strengthened its influence in the global medical technology market. By offering smarter, more efficient, and safer interventional solutions, the company is making significant contributions to the future of interventional medicine worldwide.

Looking ahead, WeMed Medical remains dedicated to its mission of "Innovation for Health." The company will continue investing heavily in research and development, with innovation as its core driving force. Through the introduction of advanced and intelligent interventional medical equipment, WeMed Medical aims to enhance healthcare efficiency and improve patient experiences globally.

Furthermore, the company will actively strengthen international collaborations, accelerating the global adoption of cutting-edge medical technologies. By pushing the boundaries of medical innovation, WeMed Medical is poised to make a lasting impact on the global healthcare industry.